468 related articles for article (PubMed ID: 17971314)
1. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
[TBL] [Abstract][Full Text] [Related]
3. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
5. Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial.
Tzanakis IP; Papadaki AN; Wei M; Kagia S; Spadidakis VV; Kallivretakis NE; Oreopoulos DG
Int Urol Nephrol; 2008; 40(1):193-201. PubMed ID: 18193489
[TBL] [Abstract][Full Text] [Related]
6. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
7. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis.
Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S
Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256
[TBL] [Abstract][Full Text] [Related]
8. Dietary habits and counseling focused on phosphate intake in hemodialysis patients with hyperphosphatemia.
Cupisti A; D'Alessandro C; Baldi R; Barsotti G
J Ren Nutr; 2004 Oct; 14(4):220-5. PubMed ID: 15483782
[TBL] [Abstract][Full Text] [Related]
9. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized multicenter trial of sevelamer hydrochloride and calcium carbonate for the treatment of hyperphosphatemia in hemodialysis patients in Japan.
Koiwa F; Onoda N; Kato H; Tokumoto A; Okada T; Fukagawa M; Shigematsu T;
Ther Apher Dial; 2005 Aug; 9(4):340-6. PubMed ID: 16076379
[TBL] [Abstract][Full Text] [Related]
11. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Finn WF; Joy MS;
Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865
[TBL] [Abstract][Full Text] [Related]
12. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
Pai AB; Smeeding JE; Brook RA
Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
[TBL] [Abstract][Full Text] [Related]
13. Use of calcium carbonate as a phosphate binder in dialysis patients.
Hercz G; Kraut JA; Andress DA; Howard N; Roberts C; Shinaberger JH; Sherrard DJ; Coburn JW
Miner Electrolyte Metab; 1986; 12(5-6):314-9. PubMed ID: 3807829
[TBL] [Abstract][Full Text] [Related]
14. Calcium-based phosphate binders are appropriate in chronic renal failure.
Friedman EA
Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
[TBL] [Abstract][Full Text] [Related]
15. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
16. [Effect of histamine H2-receptor antagonists on the phosphorus-binding ability of phosphate binders in hemodialysis patients].
Takahashi N; Yuasa S; Hitomi H; Hashimoto M; Kiyomoto H; Uchida K; Shoji T; Hirohata M; Matsuo H
Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):610-7. PubMed ID: 9014481
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
[TBL] [Abstract][Full Text] [Related]
18. The role of magnesium binders in chronic kidney disease.
Spiegel DM
Semin Dial; 2007; 20(4):333-6. PubMed ID: 17635824
[TBL] [Abstract][Full Text] [Related]
19. Intradialytic changes of serum magnesium and their relation to hypotensive episodes in hemodialysis patients on different dialysates.
Elsharkawy MM; Youssef AM; Zayoon MY
Hemodial Int; 2006 Oct; 10 Suppl 2():S16-23. PubMed ID: 17022745
[TBL] [Abstract][Full Text] [Related]
20. [Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].
Kiss D; Battegay M; Meier C; Lyrer A
Schweiz Med Wochenschr; 1990 Mar; 120(9):295-8. PubMed ID: 2315655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
